"Cheaper Weight Loss Drug Challenges Novo Nordisk as Eli Lilly Gains FDA Approval"

Eli Lilly has received approval for its weight loss-aiding drug, Zepbound, which can also be used to treat diabetes. The drug was found to help patients lose 18% of their body weight in clinical trials. With a price of $1,059.87 per month, Zepbound is nearly $300 cheaper than Novo Nordisk's rival drug, Wegovy. This marks the first real test for Novo Nordisk's dominance in the weight loss market, as Eli Lilly enters the competition. The weight loss market is projected to reach $100 billion by 2035.